JP2018522571A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522571A5
JP2018522571A5 JP2018506513A JP2018506513A JP2018522571A5 JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5 JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5
Authority
JP
Japan
Prior art keywords
seq
cells
cancer
domain
hexameric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/069175 external-priority patent/WO2017025610A1/en
Publication of JP2018522571A publication Critical patent/JP2018522571A/ja
Publication of JP2018522571A5 publication Critical patent/JP2018522571A5/ja
Pending legal-status Critical Current

Links

JP2018506513A 2015-08-12 2016-08-11 Ｇｉｔｒｌ融合タンパク質およびその使用 Pending JP2018522571A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204212P 2015-08-12 2015-08-12
US62/204,212 2015-08-12
US201662350447P 2016-06-15 2016-06-15
US62/350,447 2016-06-15
PCT/EP2016/069175 WO2017025610A1 (en) 2015-08-12 2016-08-11 Gitrl fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2018522571A JP2018522571A (ja) 2018-08-16
JP2018522571A5 true JP2018522571A5 (OSRAM) 2019-09-12

Family

ID=56740217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506513A Pending JP2018522571A (ja) 2015-08-12 2016-08-11 Ｇｉｔｒｌ融合タンパク質およびその使用

Country Status (17)

Country Link
US (2) US10428131B2 (OSRAM)
EP (1) EP3334758A1 (OSRAM)
JP (1) JP2018522571A (OSRAM)
KR (1) KR20180033588A (OSRAM)
CN (1) CN108026158A (OSRAM)
AU (1) AU2016306625A1 (OSRAM)
BR (1) BR112018002039A2 (OSRAM)
CA (1) CA2994346A1 (OSRAM)
CL (1) CL2018000358A1 (OSRAM)
CO (1) CO2018002450A2 (OSRAM)
HK (2) HK1250043A1 (OSRAM)
IL (1) IL257113A (OSRAM)
MX (1) MX2018001787A (OSRAM)
RU (1) RU2018108236A (OSRAM)
TW (1) TW201718632A (OSRAM)
WO (1) WO2017025610A1 (OSRAM)
ZA (1) ZA201801640B (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095423A2 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US11919939B2 (en) * 2017-05-23 2024-03-05 Université De Genève Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CU20210002A7 (es) 2018-07-10 2021-08-06 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
CN112601761A (zh) * 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20230203101A1 (en) * 2020-04-22 2023-06-29 POSTECH Research and Business Development Foundation Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
EP4165071A4 (en) * 2020-06-15 2024-07-17 Academia Sinica HUMANIZED AC2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN113429488B (zh) * 2021-07-14 2022-08-30 海正生物制药有限公司 GITR/TGF-β双靶向融合蛋白及其用途
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ZA200509143B (en) * 2003-05-23 2007-03-28 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
ES2605380T3 (es) * 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
CN101801413A (zh) * 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP3148573A4 (en) 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof

Similar Documents

Publication Publication Date Title
RU2018108236A (ru) Слитые белки на основе gitrl и пути их применения
US12173082B2 (en) Bispecific polypeptides against CD137
US11780928B2 (en) Polypeptides
US20220169751A1 (en) Multimeric ox40 binding molecules and uses thereof
TWI819024B (zh) 結合至ｉｌｔ４的抗體
AU2017299610B2 (en) Multimeric CD40 binding molecules and uses thereof
AU2015321546B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
JP2021118754A (ja) Ｃｄ３８に結合する抗体治療剤
CA3142738A1 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
CN110709421A (zh) 针对ox40和ctla-4的双特异性抗体
RU2016150096A (ru) Белки слияния на основе ox40l и пути их применения
JP7128819B2 (ja) Ａｄａｍ９結合分子、およびその使用方法
CN116333138A (zh) Pd-1结合分子和其使用方法
WO2018217988A9 (en) MODIFIED IGG1 FC DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS WITH THE SAME
US20220073635A1 (en) Novel polypeptides
US11873348B2 (en) Peptides
WO2022125712A9 (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CA3220027A1 (en) Bispecific fc fusion proteins with spd-1 and il-15
HK40073076A (en) Anti-cd137 antibodies
HK40004686B (en) Novel bispecific polypeptides against cd137
HK1241895B (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
HK1241895A1 (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof